Lizheng Shi

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 26:125-34. 2004
  2. ncbi Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial
    Baojin Zhu
    Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 21:555-64. 2005
  3. ncbi Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 20:1371-6. 2004
  4. ncbi Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid
    Madhav A Namjoshi
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Bldg 75 05, DC1758, Indianapolis, IN 46285, USA
    J Affect Disord 81:223-9. 2004
  5. doi Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe
    Cliff Molife
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Diabetes Technol Ther 11:529-38. 2009
  6. doi Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA
    Psychiatr Serv 59:315-7. 2008
  7. ncbi The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Affect Disord 82:373-83. 2004
  8. doi Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis
    Manjiri Pawaskar
    Eli Lilly and Company and Lilly USA, LLC, Indianapolis, IN 46285, USA
    J Med Econ 14:16-27. 2011
  9. ncbi Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes
    Lizheng Shi
    Department of Health Systems Management, Tulane University, New Orleans, LA, USA
    Curr Med Res Opin 22:961-6. 2006
  10. doi Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008

Detail Information

Publications16

  1. ncbi Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 26:125-34. 2004
    ..Improving patients' health-related quality of life (HRQOL) could be a treatment goal for bipolar depression...
  2. ncbi Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial
    Baojin Zhu
    Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 21:555-64. 2005
    ....
  3. ncbi Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 20:1371-6. 2004
    ....
  4. ncbi Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid
    Madhav A Namjoshi
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Bldg 75 05, DC1758, Indianapolis, IN 46285, USA
    J Affect Disord 81:223-9. 2004
    ..The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder...
  5. doi Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe
    Cliff Molife
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Diabetes Technol Ther 11:529-38. 2009
    ..These findings have potential clinical and policy implications for patients, diabetes care providers, and/or payers to make evidence-based decisions regarding ways to facilitate initiation and management of insulin therapy...
  6. doi Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA
    Psychiatr Serv 59:315-7. 2008
    ..This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia...
  7. ncbi The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Affect Disord 82:373-83. 2004
    ..This study compares hospital use, suicide risk and health care costs of antidepressant patients with recognized bipolar disorders (recognized-BP) and unrecognized bipolar disorders (unrecognized-BP) with non-bipolar (non-BP) patients...
  8. doi Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis
    Manjiri Pawaskar
    Eli Lilly and Company and Lilly USA, LLC, Indianapolis, IN 46285, USA
    J Med Econ 14:16-27. 2011
    ..To examine resource utilization and healthcare costs associated with the use of exenatide versus glargine in type 2 diabetes (T2D) patients...
  9. ncbi Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes
    Lizheng Shi
    Department of Health Systems Management, Tulane University, New Orleans, LA, USA
    Curr Med Res Opin 22:961-6. 2006
    ..The objective of this study was to describe clinical and work functional outcomes associated with 6-month open-label olanzapine treatment for bipolar I disorder...
  10. doi Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008
    ..This study identifies latent classes defined by varying degrees of adherence to antipsychotic drug therapy and examines the sociodemographic, clinical, and resource utilization correlates associated with membership in each adherence class...
  11. ncbi Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1900, New Orleans, LA 70112, USA
    Psychiatr Serv 58:482-8. 2007
    ....
  12. ncbi The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    J Affect Disord 97:171-9. 2007
    ..The cost of unrecognized bipolar disorders over time is unknown...
  13. pmc The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)
    Ronald C Kessler
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA
    Biol Psychiatry 58:668-76. 2005
    ..To estimate the prevalence and correlates of clinician-diagnosed DSM-IV nonaffective psychosis (NAP) in a national household survey...
  14. ncbi Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis
    Howard G Birnbaum
    Analysis Group, Inc, 111 Huntington Avenue, Boston, MA 02466, USA
    J Clin Psychiatry 64:1201-9. 2003
    ..This retrospective study compared treatment patterns and costs for patients with recognized and unrecognized bipolar disorder with those of depressed patients without a bipolar disorder claim...
  15. ncbi Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, USC School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    Health Policy 65:301-11. 2003
    ..However, while some expansion in overall antidepressant use may have been desired, the clinical validity of this expansion cannot be determined based on the results presented here...
  16. ncbi A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA
    Clin Ther 24:1939-59; discussion 1938. 2002
    ..The California Medicaid (Medi-Cal) program removed prior authorization restrictions for 2 selective serotonin reuptake inhibitors (SSRIs), fluoxetine and paroxetine, in May 1996...